GRANULES INDIA Latest Share Price (GRANULES)
TODAY IN ONE LINE
GRANULES dropped 3.6% on light volume, lagging Nifty's -1.6% move, supported by recent strong earnings.
With a market cap of ₹22,149.72 Cr., it trades at a P/E of 30.11. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GRANULES INDIA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 31.3% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 84.2% and Profit up 150.8%
- ●Healthy Operating MarginsOPM is structurally strong at 16.8%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.26x
- ●FII AccumulationFII holding increased by 2.79% QoQ
- ●Promoter BuyingPromoters increased holdings by 36.74% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest GRANULES INDIA News
What changed recently?
Recent events, corporate actions, and announcements.
GRANULES INDIA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GRANULES INDIA, framed against the sector median so the premium or discount is obvious at a glance.
GRANULES INDIA trades at a P/E of 30.11× and P/B of 3.96×, against the Healthcare sector median P/E of 45.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GRANULES INDIA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for GRANULES INDIA — derived from the latest tape, not yesterday's close.
GRANULES INDIA last traded at ₹815.05 with an intraday range of ₹810.3–₹850 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹815.05| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 919.33 | +104.28 | +12.79% |
| R3 | 879.63 | +64.58 | +7.92% |
| R2 | 864.82 | +49.77 | +6.11% |
| R1 | 839.93 | +24.88 | +3.05% |
| PIVOT | 825.12 | 10.07 | 1.24% |
| CURRENT | 815.05 | — | — |
| S1 | 800.23 | -14.82 | -1.82% |
| S2 | 785.42 | -29.63 | -3.64% |
| S3 | 760.53 | -54.52 | -6.69% |
| S4 | 720.83 | -94.22 | -11.56% |
GRANULES is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹830.15–₹850
Trading Below opening range, showing Bearishness
GRANULES INDIA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GRANULES INDIA — consolidated or standalone — with margins, YoY growth and key ratios inline.
GRANULES INDIA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹22,149.72 Cr. and reported EPS of ₹27.21.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 4,482 | 5,366 ▲ 19.7% |
| Sales Growth YoY %Derived | -0.55% | 19.73% |
| Other Income | 13 | 20 ▲ 57.4% |
| Total Income | 4,495 | 5,386 ▲ 19.8% |
| 1,726 | 1,876 ▲ 8.7% | |
| Gross ProfitDerived | 2,756 | 3,490 ▲ 26.6% |
| Gross Margin %Derived | 61.49% | 65.04% |
| 1,811 | 2,305 ▲ 27.3% | |
| EBITDA (Operating Profit)Derived | 945 | 1,185 ▲ 25.4% |
| OPM %Derived | 21.09% | 22.09% |
| 359 | 401 ▲ 11.4% | |
| Profit Before Tax (PBT) | 660 | 785 ▲ 18.9% |
| 159 | 190 ▲ 19.7% | |
| Effective Tax %Derived | 24.03% | 24.20% |
| Total Profit for Period | 502 | 595 ▲ 18.6% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 502 | 595 ▲ 18.6% |
| Net Profit Margin %Derived | 11.19% | 11.09% |
| PAT Growth YoY %Derived | 23.74% | 18.64% |
| Earnings Per Share (EPS ₹) | 20.68 | 24.01 ▲ 16.1% |
| Diluted Shares Outstanding (Cr) | 24 | 25 ▲ 2.2% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 27 | 143 ▲ 430.3% |
| Total Expenses (incl. D&A & Interest) | 3,834 | 4,601 ▲ 20.0% |
| Material Cost % of RevenueDerived | 38.49% | 39.13% |
| Employee Cost % of RevenueDerived | 14.72% | 16.56% |
| Other Cost % of RevenueDerived | 25.68% | 26.40% |
| Interest Coverage (x)Derived | 6.97x | 7.77x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,692 | 2,279 ▲ 34.7% | 2,599 ▲ 14.0% | 3,238 ▲ 24.6% | 3,765 ▲ 16.3% | 4,512 ▲ 19.8% | 4,506 ▼ 0.1% | 4,482 ▼ 0.5% | 5,366 ▲ 19.7% | |
| Sales Growth YoY %Derived | — | 34.72% | 14.02% | 24.59% | 16.29% | 19.84% | -0.12% | -0.55% | 19.73% | |
| Other Income | 11 | 27 ▲ 146.1% | 37 ▲ 37.0% | 27 ▼ 26.5% | 18 ▼ 34.5% | 14 ▼ 21.7% | 4 ▼ 68.1% | 13 ▲ 193.5% | 20 ▲ 57.4% | |
| Total Income | 1,703 | 2,306 ▲ 35.4% | 2,635 ▲ 14.3% | 3,264 ▲ 23.9% | 3,783 ▲ 15.9% | 4,526 ▲ 19.6% | 4,511 ▼ 0.3% | 4,495 ▼ 0.4% | 5,386 ▲ 19.8% | |
896 | 1,256 ▲ 40.1% | 1,281 ▲ 2.0% | 1,391 ▲ 8.6% | 1,884 ▲ 35.4% | 2,307 ▲ 22.5% | 2,021 ▼ 12.4% | 1,726 ▼ 14.6% | 1,876 ▲ 8.7% | ||
| Gross ProfitDerived | 796 | 1,024 ▲ 28.7% | 1,318 ▲ 28.7% | 1,846 ▲ 40.1% | 1,881 ▲ 1.9% | 2,205 ▲ 17.2% | 2,485 ▲ 12.7% | 2,756 ▲ 10.9% | 3,490 ▲ 26.6% | |
| Gross Margin %Derived | 47.02% | 44.91% | 50.71% | 57.03% | 49.97% | 48.86% | 55.15% | 61.49% | 65.04% | |
517 | 640 ▲ 23.7% | 792 ▲ 23.9% | 991 ▲ 25.1% | 1,159 ▲ 17.0% | 1,291 ▲ 11.4% | 1,629 ▲ 26.2% | 1,811 ▲ 11.1% | 2,305 ▲ 27.3% | ||
| EBITDA (Operating Profit)Derived | 278 | 384 ▲ 37.9% | 525 ▲ 36.8% | 855 ▲ 62.8% | 722 ▼ 15.6% | 914 ▲ 26.5% | 856 ▼ 6.3% | 945 ▲ 10.4% | 1,185 ▲ 25.4% | |
| OPM %Derived | 16.46% | 16.85% | 20.22% | 26.42% | 19.18% | 20.25% | 18.99% | 21.09% | 22.09% | |
109 | 134 ▲ 22.6% | 192 ▲ 43.1% | 178 ▼ 7.3% | 182 ▲ 2.3% | 240 ▲ 32.2% | 313 ▲ 30.2% | 359 ▲ 14.8% | 401 ▲ 11.4% | ||
| Profit Before Tax (PBT) | 180 | 277 ▲ 53.8% | 426 ▲ 53.8% | 704 ▲ 65.5% | 558 ▼ 20.8% | 687 ▲ 23.1% | 547 ▼ 20.4% | 660 ▲ 20.6% | 785 ▲ 18.9% | |
63 | 89 ▲ 40.6% | 116 ▲ 29.9% | 155 ▲ 33.9% | 145 ▼ 6.2% | 171 ▲ 17.4% | 142 ▼ 16.8% | 159 ▲ 11.8% | 190 ▲ 19.7% | ||
| Effective Tax %Derived | 35.22% | 32.20% | 27.19% | 21.99% | 26.03% | 24.82% | 25.93% | 24.03% | 24.20% | |
| Total Profit for Period | 133 | 236 ▲ 78.3% | 335 ▲ 41.9% | 549 ▲ 63.8% | 413 ▼ 24.9% | 517 ▲ 25.2% | 405 ▼ 21.5% | 502 ▲ 23.7% | 595 ▲ 18.6% | |
| Less: Non-controlling Interests | — | — | — | — | 0 | — ▼ 100.0% | — | — | — | |
| Net Profit (Owner's PAT)Derived | 133 | 236 ▲ 78.3% | 335 ▲ 41.9% | 549 ▲ 63.8% | 413 ▼ 24.9% | 517 ▲ 25.2% | 405 ▼ 21.5% | 502 ▲ 23.7% | 595 ▲ 18.6% | |
| Net Profit Margin %Derived | 7.84% | 10.37% | 12.91% | 16.97% | 10.96% | 11.45% | 8.99% | 11.19% | 11.09% | |
| PAT Growth YoY %Derived | — | 78.30% | 41.87% | 63.82% | -24.88% | 25.16% | -21.54% | 23.74% | 18.64% | |
| Earnings Per Share (EPS ₹) | 5.22 | 9.30 ▲ 78.2% | 13.19 ▲ 41.8% | 22.18 ▲ 68.2% | 16.64 ▼ 25.0% | 21.34 ▲ 28.2% | 16.72 ▼ 21.6% | 20.68 ▲ 23.7% | 24.01 ▲ 16.1% | |
| Diluted Shares Outstanding (Cr) | 25 | 25 ▲ 0.2% | 25 ▲ 0.0% | 25 ▼ 2.6% | 25 ▲ 0.1% | 24 ▼ 2.4% | 24 ▲ 0.1% | 24 ▲ 0.1% | 25 ▲ 2.2% | |
| Share of Profit from Associates/JVs | 16 | 49 ▲ 204.9% | 25 ▼ 47.7% | — ▼ 100.0% | — | — | — | — | — | |
| Other Comprehensive Income (Net of Tax) | 1 | 13 ▲ 1158.5% | 2 ▼ 83.2% | -26 ▼ 1297.3% | 40 ▲ 253.2% | 57 ▲ 42.0% | 21 ▼ 64.0% | 27 ▲ 31.8% | 143 ▲ 430.3% | |
| Total Expenses (incl. D&A & Interest) | 1,523 | 2,029 ▲ 33.3% | 2,210 ▲ 8.9% | 2,560 ▲ 15.9% | 3,225 ▲ 26.0% | 3,839 ▲ 19.0% | 3,964 ▲ 3.3% | 3,834 ▼ 3.3% | 4,601 ▲ 20.0% | |
| Material Cost % of RevenueDerived | 53.37% | 58.75% | 50.60% | 49.12% | 54.09% | 52.14% | 49.00% | 38.49% | 39.13% | |
| Employee Cost % of RevenueDerived | 9.77% | 9.21% | 9.97% | 12.61% | 10.66% | 10.47% | 13.27% | 14.72% | 16.56% | |
| Other Cost % of RevenueDerived | 20.80% | 18.86% | 20.52% | 18.00% | 20.12% | 18.14% | 22.88% | 25.68% | 26.40% | |
| Interest Coverage (x)Derived | 6.12x | 9.79x | 14.37x | 26.78x | 24.28x | 13.04x | 6.13x | 6.97x | 7.77x |
GRANULES INDIA segment analysis : revenue and profit mix.
Disclosed business segments at GRANULES INDIA with their share of revenue and profit, switchable between consolidated and standalone reporting.
GRANULES INDIA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GRANULES INDIA.
Our AI distills the core fundamental drivers supporting GRANULES INDIA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GRANULES INDIA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 32.6% YoY; TTM EPS grew 31.3% YoY, strong earnings acceleration.
TTM revenue grew 22.8% YoY, demonstrating robust top-line momentum in pharma sector.
Operating cash flow per share ₹32.01 demonstrates strong liquidity generation capability.
Debt-to-equity ratio 0.30x remains moderate, providing financial flexibility for growth.
DII holding rose from 5.03% to 23.52%, shows domestic institutional support.
Key Risks.
Free cash flow turned negative ₹-389.86 Cr in FY26 after positive ₹270.28 Cr in FY25.
ROE 11.70% and ROCE 12.47% lag peer medians, signaling capital efficiency concerns.
FII holdings fell from 23.90% to 13.24%, signals reduced foreign investor conviction.
Latest quarterly sales ₹801.88 Cr down 45.70% YoY; quarterly PAT ₹71.75 Cr down 60.13% YoY.
Operating margin 16.65% trails peer median 22.86%, competitive disadvantage evident.
Flip Conditions.
Valuation risk. a P/E above 39 (~0.9× the sector multiple of 45.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
GRANULES INDIA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GRANULES INDIA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GRANULES INDIA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GRANULES INDIA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
GRANULES INDIA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GRANULES INDIA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GRANULES INDIA stood at 58.1% of traded volume, against a 20-day average of 51.6%.
GRANULES INDIA announcements: results, concalls, ratings, M&A.
Filings GRANULES INDIA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GRANULES INDIA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 136 documents below.
General Updates
Granules India Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Granules India Limited has informed the Exchange about Link of Recording
Analysts/Institutional Investor Meet/Con. Call Updates
Granules India Limited has informed the Exchange about Schedule of meet
Trading Window
Granules India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Analysts/Institutional Investor Meet/Con. Call Updates
Granules India Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
GRANULES INDIA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GRANULES INDIA has declared, sequenced by announce and record date.
GRANULES INDIA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About GRANULES INDIA: business, sector, key facts.
What GRANULES INDIA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GRANULES INDIA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GRANULES, BSE: 532482.
Granules India Limited is a prominent player in the pharmaceutical industry, specializing in the manufacture and sale of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates, and Finished Dosages (FDs). Their operations span both the domestic Indian market and international markets, demonstrating a significant global reach within the pharmaceutical supply chain. The company's diverse product portfolio caters to a wide range of therapeutic areas, showcasing its expertise across various medicinal applications.
A core component of Granules India's business is the production of APIs. These are the fundamental building blocks for many medications and Granules offers a substantial array, encompassing anti-retrovirals (used in HIV/AIDS treatment), anti-hypertensives (for blood pressure management), anti-histamines (treating allergies), anti-infectives (combatting infections), analgesics (pain relievers), anti-coagulants (blood thinners), anti-fibriotics (treating heart conditions), and platelet inhibitors (preventing blood clot formation). This broad spectrum highlights the company's comprehensive capabilities in API synthesis and manufacturing.
Beyond APIs, Granules India also offers finished dosage forms (FDs) including tablets, caplets, and press-fit capsules. These are supplied in various packaging formats such as bulk quantities, blister packs, and bottles, catering to different client needs and distribution channels. The company further distinguishes itself by manufacturing high potent products, typically requiring specialized handling and expertise, along with other products catering to the oncology (cancer treatment) sector. This demonstrates a commitment to serving high-demand and specialized pharmaceutical segments.
Granules India's commitment to innovation is evident in its provision of development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. These complex molecules are increasingly important in modern medicine, and the company's investment in this area positions it at the forefront of pharmaceutical advancements. This diversification across various stages of pharmaceutical production, from basic APIs to complex finished dosages and specialized molecules, strengthens its position in the industry and allows for greater resilience against market fluctuations.
Established in 1984 and headquartered in Hyderabad, India, Granules India Limited has a long history of operation and a strong foothold in the global pharmaceutical landscape. The company's integrated approach, covering a wide range of pharmaceutical products and services, establishes it as a key supplier within the intricate and globally interconnected pharmaceutical supply chain.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GRANULES INDIA (GRANULES).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GRANULES INDIA (GRANULES)?
The current share price of GRANULES INDIA (GRANULES) is ₹815.05. Today, the stock has declined by ₹30.25 (3.58%), trading in a range of ₹810.30 to ₹850.00. The stock opened at ₹850.00 with a trading volume of 6,71,015 shares.
02Is GRANULES INDIA stock a good investment for long-term?
GRANULES INDIA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹22,149.72 Cr., P/E ratio of 30.11, ROE of 11.7%, and ROCE of 12.47%. The dividend yield stands at 0.21%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GRANULES INDIA stock?
The 52-week high price of GRANULES INDIA (GRANULES) is ₹923.65, while the 52-week low is ₹529.85. Currently trading at ₹815.05, the stock is 53.83% above its 52-week low and 11.76% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GRANULES INDIA stock at the current price?
Whether to buy GRANULES INDIA stock at ₹815.05 depends on multiple factors. The stock is currently trading with a P/E ratio of 30.11 and P/B ratio of 3.96. Today's performance shows a loss of 3.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GRANULES INDIA and when is the next dividend?
GRANULES INDIA offers a dividend yield of 0.21%, which means for every ₹100 invested at the current price of ₹815.05, you can expect to receive approximately ₹0.21 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GRANULES INDIA?
GRANULES INDIA's key financial metrics include: P/E Ratio: 30.11, P/B Ratio: 3.96, ROE: 11.7%, ROCE: 12.47%, Dividend Yield: 0.21%, EPS: ₹27.21, Book Value: ₹205.21, and Debt-to-Equity: 0.26. The company's market cap stands at ₹22,149.72 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GRANULES INDIA stock performing today in the market?
GRANULES INDIA stock opened at ₹850.00 and is currently trading at ₹815.05, showing a decline of ₹30.25 (3.58%). The intraday high is ₹850.00 and low is ₹810.30. The trading volume stands at 6,71,015 shares, indicating moderate market participation today.
08What is the P/E ratio of GRANULES INDIA and what does it indicate?
GRANULES INDIA has a Price-to-Earnings (P/E) ratio of 30.11, which means investors are willing to pay 30.11 for every ₹1 of earnings. With an EPS of ₹27.21, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GRANULES INDIA (GRANULES) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.